The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
Shying He
Advertisement
Articles by Shying He
Advertisement
Latest Updated Articles
China’s 2022 NRDL OutlookOctober 3rd 2022
Advertisement
Advertisement
Trending on PharmExec
1
Rebuilding Clinical Data Workflows for the AI Era
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5